Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Study Type
Study Phase
Phase 2
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: finasteride 5mg PO OD
Type: Drug
Overall Status
The purpose of this study is to study the effect of hormone therapies (androgen pathway modification) on the outcomes of patients with lung cancer. This information may be of benefit for future treatment strategies, prevention and control.

In this study, the protein where testosterone binds, called the androgen receptor (AR), will be measured in samples from the patient's biopsy and surgical tumor samples. The investigators will look at a marker of how fast the cancer is growing (Ki67) before using finasteride from your biopsy specimen. Finasteride will be taken from the day of consent until the day of the patient's surgery. This marker will be measured again after using finasteride from the surgical specimen. The investigators will be looking for a decrease in the Ki67 from the patient's biopsy specimen to the surgical specimen as an indicator that this medication is blocking tumour growth.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Male
Criteria: Inclusion Criteria:

- male

- age >18

- biopsy-proven non-small cell lung cancer

- surgical intervention planned

Exclusion Criteria:

- current use of 5-alpha reductase inhibitor

- previous diagnosis of prostate cancer

- previous hypersensitivity to 5-alpha reductase inhibitor
Health Sciences Centre
Winnipeg, Manitoba, Canada
Status: Recruiting
Contact: M Pitz, MD - 204-787-1815
Start Date
June 2014
CancerCare Manitoba
CancerCare Manitoba
Record processing date processed this data on July 28, 2015 page